- Home
- BIAF vs PRPH Comparison
BIAF vs PRPH Comparison
Compare BIAF & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- PRPH
- Stock Information
- Founded
- BIAF 2014
- PRPH 1989
- Country
- BIAF United States
- PRPH United States
- Employees
- BIAF N/A
- PRPH N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- PRPH Health Care
- Exchange
- BIAF Nasdaq
- PRPH Nasdaq
- Market Cap
- BIAF 12.2M
- PRPH 10.7M
- IPO Year
- BIAF 2022
- PRPH 1997
- Fundamental
- Price
- BIAF $0.75
- PRPH $0.37
- Analyst Decision
- BIAF Hold
- PRPH
- Analyst Count
- BIAF 1
- PRPH 0
- Target Price
- BIAF N/A
- PRPH N/A
- AVG Volume (30 Days)
- BIAF 28.2M
- PRPH 1.7M
- Earning Date
- BIAF 05-14-2025
- PRPH 03-31-2025
- Dividend Yield
- BIAF N/A
- PRPH N/A
- EPS Growth
- BIAF N/A
- PRPH N/A
- EPS
- BIAF N/A
- PRPH N/A
- Revenue
- BIAF $9,362,022.00
- PRPH $6,770,000.00
- Revenue This Year
- BIAF $25.19
- PRPH N/A
- Revenue Next Year
- BIAF $20.00
- PRPH $64.06
- P/E Ratio
- BIAF N/A
- PRPH N/A
- Revenue Growth
- BIAF 269.68
- PRPH N/A
- 52 Week Low
- BIAF $0.24
- PRPH $0.22
- 52 Week High
- BIAF $3.16
- PRPH $7.48
- Technical
- Relative Strength Index (RSI)
- BIAF 60.32
- PRPH 44.34
- Support Level
- BIAF $0.24
- PRPH $0.35
- Resistance Level
- BIAF $1.55
- PRPH $0.52
- Average True Range (ATR)
- BIAF 0.13
- PRPH 0.08
- MACD
- BIAF 0.08
- PRPH -0.00
- Stochastic Oscillator
- BIAF 38.64
- PRPH 23.00
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.